Source disclosure: February 17, 2026
StemRIM Inc. [4599.T]
TOKYO, Feb 17 (Pulse News Wire) – StemRIM Inc. (4599.T) secured a patent in Canada for a novel treatment method targeting cartilage diseases using its regenerative medicine candidate, Ledasumtid (HMGB1 fragment peptide).
The patent covers conditions such as traumatic cartilage defects, osteoarthritis, osteochondritis dissecans, meniscal injuries, traumatic arthritis, inflammatory arthritis, and infectious arthritis. Ledasumtid, developed from a compound licensed to Shionogi & Co., Ltd., has shown potential in mobilizing bone marrow-derived mesenchymal stem cells (MSCs) through intravenous administration, which could promote tissue repair and regeneration in damaged knee joints. The company believes this development enhances the therapeutic scope of Ledasumtid in Canada and supports future drug development efforts for treating cartilage diseases.
The patent filing number is 3,117,107. Registration details, including the publication number, are pending. There will be no impact on the fiscal year ending June 2026 earnings, but StemRIM will promptly disclose any significant developments related to this patent.
AI-translated content. 🟢 Confidence: High See terms • Original filing